Intra-Cellular Therapies, Inc. announced top-line results from two Phase III trials (Study 401 and Study 404) evaluating lumateperone as monotherapy in the treatment of major depressive episodes associated with Bipolar I or Bipolar II disorder.     In Study 404, lumateperone 42 mg met the primary endpoint for improvement in depression as measured by change from baseline versus placebo on the MADRS total score.  Study 404 also met its key secondary endpoint, Clinical Global Impression Scale for...